CA2172245A1 - Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein - Google Patents

Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein

Info

Publication number
CA2172245A1
CA2172245A1 CA002172245A CA2172245A CA2172245A1 CA 2172245 A1 CA2172245 A1 CA 2172245A1 CA 002172245 A CA002172245 A CA 002172245A CA 2172245 A CA2172245 A CA 2172245A CA 2172245 A1 CA2172245 A1 CA 2172245A1
Authority
CA
Canada
Prior art keywords
negative bacterial
bpi
administration
bactericidal
permeability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002172245A
Other languages
French (fr)
Other versions
CA2172245C (en
Inventor
Jonathan Cohen
Ada H. C. Kung
Lewis H. Lambert, Jr.
Roger G. Ii Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Corp
Original Assignee
Jonathan Cohen
Ada H. C. Kung
Lewis H. Lambert, Jr.
Roger G. Ii Little
Xoma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jonathan Cohen, Ada H. C. Kung, Lewis H. Lambert, Jr., Roger G. Ii Little, Xoma Corporation filed Critical Jonathan Cohen
Publication of CA2172245A1 publication Critical patent/CA2172245A1/en
Application granted granted Critical
Publication of CA2172245C publication Critical patent/CA2172245C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751Bactericidal/permeability-increasing protein [BPI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742Bactericidal/Permeability-increasing protein [BPI]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to methods and compositions for treating gram-negative bacterial infections, using BPI protein products.
Co-treatment, or concurrent administration, of BPI protein product with an antibiotic in treatment of gram-negative bacterial infections improves the therapeutic effectiveness of the antibiotic, including increasing antibiotic susceptibility of gram-negative bacteria and reversing resistance of the bacteria to antibiotics.
CA002172245A 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein Expired - Fee Related CA2172245C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12565193A 1993-09-22 1993-09-22
US08/125,651 1993-09-22
US27340194A 1994-07-11 1994-07-11
US08/273,401 1994-07-11
PCT/US1994/011225 WO1995008344A1 (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic

Publications (2)

Publication Number Publication Date
CA2172245A1 true CA2172245A1 (en) 1995-03-30
CA2172245C CA2172245C (en) 2003-04-08

Family

ID=26823793

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002172245A Expired - Fee Related CA2172245C (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein

Country Status (13)

Country Link
US (2) US5523288A (en)
EP (1) EP0759774B1 (en)
JP (1) JPH09502987A (en)
AT (1) ATE218880T1 (en)
AU (1) AU695814B2 (en)
CA (1) CA2172245C (en)
DE (1) DE69430823T2 (en)
DK (1) DK0759774T3 (en)
ES (1) ES2178656T3 (en)
HK (1) HK1014155A1 (en)
NZ (1) NZ275205A (en)
PT (1) PT759774E (en)
WO (1) WO1995008344A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
JPH09502987A (en) * 1993-09-22 1997-03-25 ゾーマ コーポレイション Method of treating Gram-negative bacterial infections by administration of bactericidal / permeabilized (BPI) protein products and antibiotics
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
JP2001520631A (en) * 1995-07-20 2001-10-30 ゾーマ コーポレイション Antifungal peptide
AUPN771596A0 (en) * 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
PT914144E (en) * 1996-05-10 2001-05-31 Univ Texas THERAPEUTIC UTILIZATIONS OF BIP PROTEIN PRODUCTS AGAINST HUMAN MENINGOCOCCEMIA
WO1997044056A1 (en) * 1996-05-23 1997-11-27 Xoma Corporation Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
WO1998050576A1 (en) * 1997-05-02 1998-11-12 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999052357A1 (en) * 1998-04-14 1999-10-21 Ribogene, Inc. Assays for inhibitors of bacterial translation initiation factor 3
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
US6696239B1 (en) * 2000-04-20 2004-02-24 Biolog, Inc. Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials
US20020173464A1 (en) * 2000-12-01 2002-11-21 King George L. Modulation of pericyte proliferation
WO2002060879A2 (en) 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
AU2002328203C1 (en) 2001-08-24 2009-01-08 Migenix Inc. Antimicrobial and anti-inflammatory peptides
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
MXPA05007743A (en) * 2003-01-21 2005-11-04 Ecopia Biosciences Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals.
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
WO2005024025A1 (en) * 2003-09-11 2005-03-17 Ecopia Biosciences Inc. Polyene polyketides and methods of production
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
EP1741440A1 (en) * 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
US8871929B2 (en) 2010-08-03 2014-10-28 Merck Sharp & Dohme Corp. Fused-imidazoyl compounds useful as antimicrobial agents
CN103443096B (en) 2011-01-14 2016-06-29 沃泰克斯药物股份有限公司 Gyrase and topoisomerase I V inhibitor
WO2012112438A2 (en) * 2011-02-16 2012-08-23 The Penn State Research Foundation Anti-microbial agents and compositions and methods of production and use thereof
EP2721026B1 (en) 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphate esters of gyrase and topoisomerase inhibitors
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2014026143A1 (en) * 2012-08-09 2014-02-13 Pono Corporation Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof
WO2014160814A1 (en) * 2013-03-26 2014-10-02 Rutgers, The State University Of New Jersey Synthetic and enhanced bacterial killing involving bicyclomycin
JP2018529689A (en) * 2015-09-17 2018-10-11 ソウル大学校産学協力団Seoul National University R&Db Foundation Cleaved or folded helical peptides or peptide analogs showing antibacterial activity against gram-negative bacteria and uses thereof
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US20210023101A1 (en) * 2017-07-19 2021-01-28 The University Of North Carolina At Chapel Hill Potentiation of antibiotic effect

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5028251A (en) * 1973-07-12 1975-03-22
JPS55134471A (en) * 1979-04-04 1980-10-20 Toshiba Corp Sales management system in small-scale computer constitution
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
JPS60128596A (en) * 1983-12-15 1985-07-09 東芝テック株式会社 Electronic cash register
JPS619790A (en) * 1984-06-25 1986-01-17 オムロン株式会社 Electronic cash register
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
EP1659132A1 (en) * 1987-08-11 2006-05-24 New York University Biologically active bactericidal/permeability-increasing protein fragments
AU3772289A (en) * 1988-06-23 1990-01-12 Associates Of Cape Cod, Inc. Endotoxin binding protein and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
EP0563222B1 (en) * 1990-12-03 1998-02-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5156665A (en) * 1991-01-03 1992-10-20 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl compounds and isothiazolones and methods of controlling microbes
EP0605653A4 (en) * 1991-09-26 1995-03-15 Incyte Pharma Inc A new form of liposaccharide binding protein (lbp).
ES2132239T3 (en) * 1992-05-19 1999-08-16 Xoma Corp IMPROVED METHODS FOR THE PREPARATION OF BINDING PROTEINS TO ENDOTOXINS.
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1994017819A1 (en) * 1993-02-02 1994-08-18 Xoma Corporation Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
DE69410254T2 (en) * 1993-03-12 1998-12-17 Xoma Corp TREATMENT OF MYCOBACTERIAL DISEASES THROUGH THE ADMINISTRATION OF BACRERIAL-KILLING, PLEASURE-INCREASING PROTEIN FRAGMENTS
DK0690872T3 (en) * 1993-03-12 1999-05-10 Xoma Corp Biologically active peptides from bacterial / permeability enhancing protein functional domains and uses thereof
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
EP1129718A3 (en) * 1993-03-12 2002-05-22 XOMA Technology Ltd. Therapeutic uses of bactericidal/permeability increasing protein products
JPH09502987A (en) * 1993-09-22 1997-03-25 ゾーマ コーポレイション Method of treating Gram-negative bacterial infections by administration of bactericidal / permeabilized (BPI) protein products and antibiotics

Also Published As

Publication number Publication date
EP0759774A1 (en) 1997-03-05
PT759774E (en) 2002-11-29
HK1014155A1 (en) 1999-09-24
AU695814B2 (en) 1998-08-20
NZ275205A (en) 1998-03-25
US6140306A (en) 2000-10-31
ES2178656T3 (en) 2003-01-01
JPH09502987A (en) 1997-03-25
AU8074094A (en) 1995-04-10
CA2172245C (en) 2003-04-08
EP0759774B1 (en) 2002-06-12
US5523288A (en) 1996-06-04
ATE218880T1 (en) 2002-06-15
DE69430823T2 (en) 2003-02-20
WO1995008344A1 (en) 1995-03-30
DK0759774T3 (en) 2002-10-07
DE69430823D1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
CA2172245A1 (en) Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein
ATE219684T1 (en) ANTI-GRAM POSITIVE BACTERIAL METHODS AND AGENT
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
EP1283050A3 (en) Improved therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
PT806941E (en) LIPOSOMIC ANTI-BACTERIAL COMPOSITIONS OF LOW RIGIDITY
RU93004457A (en) 1-CARBES- (1-DETIA) -CEFITS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
CA2058592A1 (en) Antibacterial agents
CA2351429A1 (en) 13-membered azalides and their use as antibiotic agents
CA2254682A1 (en) Method of treating eye infections with azithromycin
EP1019084A4 (en) Novel antimicrobial polypeptide and methods of use
DE60027472T2 (en) METHOD AND COMPOSITION FOR TREATMENT AND / OR PROPHYLAXIS OF ANTIBIOTICUM RESISTANT MICROORGANISM INFECTIONS
AU7792294A (en) Antibacterial composition containing multimeric alpha-lactalbumin
HUP0401586A2 (en) Antibacterial agent
CA2468036A1 (en) A method of treating bacterial infections using gemifloxacin or a salt thereof and a .beta.-lactam antibiotic
Calandra Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients.
ZA947394B (en) Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
Kern et al. In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives
Bartoloni et al. The influence of ofloxacin versus trimethoprim-sulfamethoxazole on the aerobic flora in granulocytopenic subjects
Liubchenko et al. Experimental technological model for the combination of antibacterial drugs that provide anti-microbial effects for treatment of staphylococcal infections
Bustamante Initial empiric therapy for fever in neutropenia
Van Der Waaij et al. Infection prevention in neutropenic patients
IT1313628B1 (en) Use of gemifloxacin compounds, which can be active against bacterial strains resistant to other antibiotics, in treatment of infections caused by respiratory tract pathogenic bacteria
RU93047438A (en) METHOD OF TREATMENT OF PUSH-INFLAMMATORY PROCESSES
ES2076107A1 (en) Macrolid antibiotic derivatives having rings with 16 members

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed